Corporate Events

Takeda Pharmaceutical Company Limited announced an embargoed version of an abstract for Phase 3 TAK-861-3002 study (RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1, which is slated to be presented at the upcoming World Sleep 2025 congress in September, was inadvertently published by the World Sleep Congress on their website. Once they became aware, they reached out to World Sleep and they have since removed the abstract. This abstract is only one of several abstracts from Phase 3 studies that will be presented at the conference. They look forward to sharing the positive results from both of Phase 3 studies at World Sleep, which, as previously disclosed, met all of the primary and secondary endpoints across all doses at week 12. These results reinforce the potential of oveporexton to transform the standard of care for people with narcolepsy type 1. Title: Efficacy and Safety of Oveporexton (TAK-861) for the Treatment of Narcolepsy Type 1: Results from a Phase 3 Randomized Study in Asia, Australia and Europe. Introduction: Narcolepsy type 1 (NT1) is a chronic, rare, neurologic disorder of hypersomnolence caused by loss of orexin-producing neurons in the hypothalamus, which regulate wakefulness, sleep, and attention through activation of orexin receptors. NT1 results in a range of symptoms including excessive daytime sleepiness, sudden muscle weakness (cataplexy), disrupted nighttime sleep, sleep paralysis, hypnagogic/hypnopompic hallucinations, and cognitive symptoms. Orexin receptor agonists are promising treatments for NT1 as currently available therapies do not target orexin deficiency. Oveporexton (TAK-861) is an investigational oral orexin receptor 2 (OX2R)-selective agonist that stimulates OX2R to restore signaling and address the underlying orexin deficiency. In a previous phase 2b study, oveporexton delivered improvements across the spectrum of NT1 symptoms, assessed by both objective and patient-reported measures, and was generally well tolerated. Here, report first results from a phase 3 study that evaluated the efficacy, safety and impact on functioning, quality of life and cognition of oveporexton in participants with NT1. Materials and methods: In this double-blind, placebo-controlled, phase 3 study (TAK-861-3002) participants were randomized 2:1 to oral oveporexton 2 mg or placebo twice daily at least 3 hours apart for 12 weeks. At the end of treatment, participants either entered the long-term extension or completed 4 weeks of follow up . Key inclusion criteria included: age 16-70 years; International Classification of Sleep Disorders, Third Edition (ICSD-3) or ICSD-3-text revision diagnosis of NT1 supported by polysomnography, multiple sleep latency testing (MSLT) or orexin cerebrospinal fluid (CSF) concentrations 110 pg/mL; Epworth Sleepiness Scale (ESS) score 11; and 4 partial/complete episodes of cataplexy/week. The primary endpoint was change from baseline in mean sleep latency on the Maintenance of Wakefulness Test (MWT) at week 12. Secondary endpoints included change from baseline in ESS total score at week 12, weekly cataplexy rate (WCR) at week 12, and occurrence of treatment-emergent adverse events (TEAE). Results: Overall, 105 participants (50 [47.6%] female) were enrolled across Asia, Australia, and Europe; 70 were randomized to oveporexton 2 mg/2 mg and 35 to placebo. At baseline, mean age was 30.7 years, mean ESS score was 17.5, mean MWT sleep latency was 4.5 minutes and median WCR was 23.5 attacks/week. At week 12, significant least square (LS) mean (95% CI) changes from baseline were achieved with oveporexton 2mg/2mg vs placebo in MWT sleep latency (20.09 [16.57, 23.61] minutes, P<0.001 vs placebo). Significant changes vs placebo were also achieved at week 12 for ESS total score (LS mean [95% CI] change from baseline: -9.53 [-11.10, -7.97], P<0.001) and WCR (Incidence rate ratio [95% CI] vs placebo: 0.25 [0.15, 0.42], P<0.001). Sixty (85.7%) oveporexton-treated participants experienced 1 TEAEs vs 15 (42.9%) placebo-treated participants; there were no serious TEAEs. The most common TEAEs with oveporexton were pollakiura (43 [61.4%]) and insomnia (40 [57.1%]). 101 (96.2%) completed study treatment, of which 100 (99.0%) enrolled into the long-term extension. Conclusions: In this phase 3 study, oveporexton treatment resulted in significant improvements on measures of sleepiness and cataplexy frequency with oveporexton versus placebo, and was generally well tolerated.

Takeda Pharmaceutical Company Limited announced consolidated impairment losses for three-month period ended June 30, 2025 . For the period, the company reported impairment losses of JPY 2,357 million against JPY 26,000 million a year ago.

Takeda Pharmaceutical Company Limited reported earnings results for the first quarter ended June 30, 2025. For the first quarter, the company reported sales was JPY 1,106,685 million compared to JPY 1,207,990 million a year ago. Net income was JPY 124,243 million compared to JPY 95,248 million a year ago. Basic earnings per share from continuing operations was JPY 79.4 compared to JPY 60.71 a year ago. Diluted earnings per share from continuing operations was JPY 78.23 compared to JPY 59.94 a year ago.

Takeda announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, devices for patients 17 years of age and older that allow HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] to be transferred from vials without using a needle in a home environment or clinical setting.2 The HYQVIA administration process consists of dual vial units (DVUs) including one vial of immunoglobulin (IG) and one vial of hyaluronidase. HyHub and HyHub Duo, which act as docking stations for these vials, were developed to simplify administration of HYQVIA by reducing the number of steps required to prepare the infusion of two DVUs or more. HYQVIA is a combination of IG and hyaluronidase for facilitated subcutaneous immunoglobulin (SCIg) infusion that is approved for treatment of adults and children two years of age and older with primary immunodeficiency (PI) and as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) in the United States.2 Depending on the indication, HYQVIA can be infused up to once monthly (every two, three or four weeks). HyHub and HyHub Duo are intended for use only with HYQVIA and the devices will be available at no additional cost to patients. It is also approved by the European Medicines Agency (EMA) as a replacement therapy in adults, children and adolescents with PI and with secondary immunodeficiency (SID) who suffer from severe or recurrent infections, effective antimicrobial treatment, and either proven specific antibody failure (PSAF) or serum IgG level of 5% of patients in the clinical trials were: Primary Immunodeficiency (PI): Local reactions, headache, antibody formation against rHuPH20, fatigue, nausea, pyrexia, and vomiting. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health attacks, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's most recent annual Report on Form 20-F. Takeda's and Takeda's most recently Annual Report on Form 20- F and Takeda's most most recent Annual Report on Form20-F and Takeda has been announced in the United States.

JKI Co., Ltd. agreed to acquire 49% stake in Teva Takeda Pharma Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502) for ¥55 billion on December 5, 2024. All the employees of the business venture in Teva Takeda Pharma Ltd. will remain employed, subject to the terms of the agreement. the consideration is subject to closing adjustments. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2025. JKI Co., Ltd. completed the acquisition of 49% stake in Teva Takeda Pharma Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502) on December 5, 2024. The consideration for the transaction is ¥56.5 billion.

Takeda Pharmaceutical Company Limited Presents at BIO Asia Taiwan 2025, Jul-23-2025 09:40 AM. Venue: TaiNEX 1 & 2, Taipei Nangang Exhibition Center, Taipei, Taiwan. Speakers: Yasuko TERAO, Head, External Scientific Engagement, R&D Global Regions Japan.

Takeda announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of Oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NNT1 is caused by the loss of orexin-producing neurons in the brain. Orexin is a key regulator of sleep and wake patterns and contributes to other essential functions including attention, mood, metabolism and resistance. Oveporexton (TAK-861) is the lead investigational orexin receptor 2 (ox2R) agonist asset in Takeda's orexin franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type1 (NT1) from the U.S. Food and Drug Administration and the Center for Drug Evaluation of China's National Medical Products Administration. The company is also investigating other orexin inhibitors in populations with orexin levels in the normal range, including TAK-360, an oral OX2R agonist initially being investigated for the treatment of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other potential indications where orexin signaling is implicated. Without limitation, forward-looking statements often include words such as "targets", "plans", "bel believes", "hopes", " continues", " aimss", "intends", "ensures", " may", "should", "would", " could", "anticipates", "estimates", " projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of environmental sustainability efforts, in enabling us to reduce greenhouse gas emissions or meet other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website.

Takeda Pharmaceutical Company Limited, Q1 2026 Earnings Call, Jul 30, 2025

Takeda Pharmaceutical Company Limited approved dividend of JPY 98 per share of common stock at the shareholders meeting held on June 25, 2025.

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human] with less than or equal to 2 ug/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). This enhanced removal capability (ERC) results in a product with IgA less than or equal to 2 Ug/mL in a 10% solution. While GAMMAGARD LIQUIDERC is not indicated specifically for IgA sensitivity in people with primary immunodeficiency, it may be an appropriate option for them based on their physician's clinical judgment. Interference with Lab Tests: false positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies. Adverse Reactions: The serious adverse reaction seen during IV clinical trials was aseptic meningitis. The most common adverse reactions observed in 5% of patients in clinical trials were headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur. Subcutaneous administration: The most common adverse reactions observed In 5% of patients in clinical trial were infusion site (local) event (rash, erythema, edema, hemorrhage, and irritation), headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, diarrhea, migraine, migraine, oropharyngeal pain, and pain in extremity. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health emergencies, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website.

Takeda Pharmaceutical Company Limited reported earnings results for the fourth quarter and full year ended March 31, 2025. For the fourth quarter, the company reported sales was JPY 1,053,400 million compared to JPY 1,050,900 million a year ago. Net loss was JPY 103,200 million compared to JPY 3,000 million a year ago. Basic loss per share from continuing operations was JPY 65.25 compared to JPY 1.92 a year ago. For the full year, sales was JPY 4,581,551 million compared to JPY 4,263,762 million a year ago. Net income was JPY 107,928 million compared to JPY 144,067 million a year ago. Basic earnings per share from continuing operations was JPY 68.36 compared to JPY 92.09 a year ago. Diluted earnings per share from continuing operations was JPY 67.23 compared to JPY 91.16 a year ago.

Takeda Pharmaceutical Company Limited has filed a Shelf Registration. Security Name: Senior Unsubordinated Unsecured Debt Securities

Takeda Pharmaceutical Company Limited, Board Meeting, Jun 25, 2025. Agenda: To consider new assignments of directors.

Takeda Pharmaceutical Company Limited announced New Assignment of Compensation Committee Members (Effective June 25, 2025). Compensation committee: Emiko Higashi (Chairperson), John Maraganore, Michel Orsinger, Miki Tsusaka and Kimberly A. Reed.

The U.S. Court of Appeals for the Ninth Circuit affirmed a class certification order in Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited, marking a watershed moment in a first-of-its-kind class action that is now in its eleventh year. The Ninth Circuit upheld the certification of a national class of third-party payers seeking damages under the Racketeer Influenced and Corrupt Organizations (RICO) Act against pharmaceutical giants Takeda Pharmaceutical Company and Eli Lilly and Company. The suit accuses both companies of conspiring to conceal the bladder cancer risks associated with the diabetes drug Actos (pioglitazone) for over a decade, exposing millions of vulnerable diabetics to a carcinogen without their consent. It is a legacy of fraud, attorneys say, and this ruling finally paves the way for a jury trial on this important case. The case is the first non-settlement national RICO class action lawsuit certified against a major pharmaceutical company. Legal experts estimate the total damages could exceed $7 billion. The Ninth Circuit's affirmation comes despite opposition from the pharmaceutical defendants and industry amici, who challenged the district court's class certification on multiple grounds. In a detailed memorandum, the appellate court rejected each of the defendants' arguments, finding that the lower court "properly conducted a 'rigorous analysis,' as required to certify a class," and adding that it "did not abuse its discretion by finding the predominance requirement satisfied." The case stems from allegations that Takeda and Eli Lilly engaged in a decade-long conspiracy to conceal Actos's significant bladder cancer risks. Internal documents revealed Takeda and Lilly knew about the bladder cancer risk as early as 1999. After the FDA mandated a bladder cancer warning for Actos in 2011, drug sales dropped by 80%, demonstrating the material impact of the fraud. Plaintiffs allege the companies knew about the bladder cancer risks but chose to hide them to protect billions in annual sales, defrauding third-party payers who paid for the medication.

Takeda Pharmaceutical Company Limited Presents at BIO International Convention 2025, Jun-17-2025 04:15 PM. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States. Speakers: Andrew Kaplan, Senior Vice President of U.S. Public Affairs, Danielle Thompson-Reynolds, Head of Manufacturing Training and Support, Manufacturing Support, MA Bio Ops, Leah G. Lindsay, Lead, R&D Science Philanthropy and Community Engagement.

Takeda Pharmaceutical Company Limited Presents at Veeva R&D Summit EU 2025, Jun-04-2025 05:00 PM. Venue: Madrid, Spain. Speakers: Sabura Matthews, Head Digital Strategy, Patient Safety Pharmacovigilance Operations.

Takeda announced that the European Commission (EC) approved ADCETRIS®? (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) - a chemotherapy regimen - in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. ADCETRIS injection for intravenous infusion has received FDA approval for eight indications: Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL) in combination with doxorubicin), vinblastine, and dacarbazine (2018). Pediatric patients 2 years and older with previously untreated high risk cHL in combination with doxorUBicin, vinblastine, and prednisone (2022). Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation (2015); Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates (2011); Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, do xorubicin, and prednisone (2018); Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen (2011); Adult patients with primary cutaneous anaplastic large cell lymphomas (pcALCL) or CD30-expressing mycosis fungoides (MF) after prior systemic therapy (2017); Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma ("DLBCL") not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CART-cell therapy, in combination with lenalidomide and a rituximab product (2025). Health Canada granted ADCETRIS approval with conditions for relapsed or refractory Hodgkin lymphoma and sALCL in 2013, and non-conditional approval for post-autologous stem cell transplantation (ASCT) consolidation treatment of Hodgkin lymphoma patients at increased risk of relapse or progression in 2017, adults with PCALCL or CD30-expressing MF who have had prior systemic therapy in 2018, for previously untreated Stage IV Hodgkin lymphoma in combination with doxorab, vinblastine, & dacarbazine in 2019, and for previously untreated adult patients with previously untreated Stage IV Hodgkin canceroma in combination with doxORubicin, vin blastine, and dacarb magazine in 2019, and for previously treated adult patients with previously untreated adult patients with newly diagnosed Stage 2b with risk factors/III/IV Hodgkin lymphoma and dacarbazine (2018).

Protagonist Therapeutics, Inc. and Takeda announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61stAmerican Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today. PV is characterized by overproduction of red blood cells (erythrocytosis), which may increase blood viscosity, or thickness, potentially resulting in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism.

Annual General Meeting of Shareholders

Takeda announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.These debilitating symptoms can markedly reduce an individual’s quality of life and severely impact job performance, academic achievement and personal relationships. Current standard of care includes polypharmacy to manage different symptoms, but none of these medicines target the underlying orexin deficiency that causes NT1. The TAK-861-2001 Phase 2b trial enrolled 112 adults aged 18-70 with NT1 globally. Participants were randomized equally to one of four dosing arms (twice-daily 0.5/0.5 mg, 2/2 mg, 2/5 mg or once-daily 7 mg) or placebo for 8 weeks. The primary and secondary endpoints from the study assessed the impact of oveporexton across subjective and objective measures of wakefulness and daytime sleepiness, cataplexy rates and safety compared to placebo. Results from the Phase 2b trial showed: The primary endpoint demonstrated substantial increases in mean sleep latency on the Maintenance of Wakefulness Test (MWT), a key measure of wakefulness, with improvements across all doses compared to placebo (adjusted p =0.001 for all comparisons) sustained over 8 weeks. The mean sleep latency on the MWT reached values consistent with normative values seen in healthy individuals. Key secondary endpoints demonstrated significant reductions in Epworth Sleepiness Scale (ESS) scores, a measure of EDS, and reductions in Weekly Cataplexy Rate (WCR) across all doses compared to placebo and were sustained over 8 weeks. The Narcolepsy Severity Scale for Clinical Trials (NSS-CT), a self-assessment scale used to assess the severity, frequency and impact across narcolepsy symptoms, and the 36-item short-form (SF-36), used to assess quality of life, were evaluated as exploratory endpoints. NSS-CT domain scores indicated marked improvements across most domains (EDS, cataplexy, hypnagogic hallucinations and sleep paralysis) while clinically meaningful improvements in quality of life as assessed with the SF-36 questionnaire were observed with all oveporexton dose groups compared to placebo. The most commonly reported treatment-emergent adverse events (TEAEs) were insomnia (43%), increased urinary urgency (30%) and frequency (29%). Most TEAEs were mild to moderate in intensity, and most started within 1-2 days of treatment and were transient. No cases of hepatotoxicity or visual disturbances were reported. The majority of participants (95%) who completed the trial enrolled in the long-term extension (LTE) study, with many patients reaching one year or more of treatment. Takeda is leading the field of orexin science with a multi-asset franchise. Oveporexton, the lead program in the franchise, is the first and only orexin agonist in Phase 3 trials. Takeda anticipates a data readout from the Phase 3 trials in calendar year 2025.

Takeda Pharmaceutical Company Limited Presents at Pharma Manufacturing World Summit 2025, May-20-2025 through May-22-2025. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: May-21-2025, Lindsey Daniel, Head of Global Operational Excellence for Takeda’s Biologics Operating Unit, Magaly Aham, Senior Vice President, Head Global Quality Compliance & Systems. May-22-2025, Magaly Aham, Senior Vice President, Head Global Quality Compliance & Systems.

Takeda Pharmaceutical Company Limited provided earnings guidance for the fiscal year ending March 31, 2026. For the period, the company expects revenue of JPY 4,530,000 million, operating profit of JPY 475,000 million, Net profit attributable to owners of the Company of JPY 228,000 million and Basic earnings per share of JPY 144.81.

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025, at 10:00 Tokyo Standard Time. Location: imperial hotel, 3rd floor, 8-50, temmabashi 1-chome, kita-ku, osaka Japan Agenda: To consider the Business Report, Consolidated Financial Statements and Unconsolidated Financial Statements for the 148th fiscal year (from April 1, 2024 to March 31, 2025); to consider the Results of audits of the Consolidated Financial Statements by the Accounting Auditor and Audit and Supervisory Committee, for the 148th fiscal year; to consider the Appropriation of Surplus; to consider the Election of Ten Directors who are not Audit and Supervisory Committee Members; and to consider the Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members.

Takeda Pharmaceutical Company Limited, Board Meeting, May 08, 2025. Agenda: To discuss Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025.

Takeda Pharmaceutical Company Limited provided dividend guidance for the fiscal year ending March 31, 2026. The company proposed Dividend Increase from JPY 196 per share to JPY 200 per share.

Takeda Pharmaceutical Company Limited provided earnings guidance for the fiscal year ending March 31, 2026. For the period, the company expects revenue of JPY 4,530 billion, operating profit of JPY 475 billion, Net profit attributable of JPY 228.0 billion, EPS of JPY 145.

Takeda Pharmaceutical Company Limited Presents at Databricks Data + AI Summit, Jun-09-2025 . Venue: San Francisco, California, United States. Speakers: Clare Bornstein, Platform Operations Lead.

Takeda Pharmaceutical Company Limited has filed a Shelf Registration in the amount of ¥500 billion. Security Name: Bonds Principal Amount: ¥500 billion

Takeda Pharmaceutical Company Limited has withdrawn its Shelf Registration dated October 26, 2018 in the amount of ¥500 billion. Security Name: Senior Subordinated Loan Bonds Principal Amount: ¥500 billion

On April 29, 2025, Novavax, Inc. (Company) entered into a collaboration and exclusive license agreement, as amended, (Amended collaboration agreement) with Takeda Pharmaceutical Company Limited (Takeda) which amends and supersedes the collaboration and exclusive license agreement, dated February 24, 2021, (the “Original Agreement,” together with the Amended Collaboration Agreement, the “Agreement”). The Original Agreement, which granted Takeda an exclusive license to develop, manufacture, and commercialize NVX-CoV2373, the Company’s vaccine candidate for the SARS-CoV-2 virus (the “Vaccine”) in Japan, has been amended so that Takeda may develop and commercialize a strain for the Vaccine that is different from the strain that the Company selects for the year, provided such Takeda selected strain must be procured from the Company. Under the Amended Collaboration Agreement, Takeda will continue to purchase the Company’s Matrix-M™ adjuvant to manufacture doses of finished Vaccine with updated adjuvant forecast and other supply terms. Under the Amended Collaboration Agreement, the Company will receive a non-refundable upfront payment of $19.5 million of which $5 million is creditable against royalties owed by Takeda for its fiscal year 2024. In addition, on an annual basis, (i) the Company will receive $2 million to compensate the Company for services provided by the Company under the Agreement, and (ii) the Company will receive an additional $8 million annual milestone payment of which $5 million is creditable against royalties owed by Takeda in its fiscal year 2025 or thereafter, if Takeda receives marketing approval of the Vaccine in that year or such approval is not necessary for such year. The parties have also updated the financial terms to replace the share of operating profits and, instead, provide the Company with a tiered royalty as a percentage of Takeda’s, its affiliates’ and sublicensees’ total net sales in the mid to high-teen percentages (subject to certain capped royalty reductions), commencing on April 1, 2024 and will continue until the latest of (a) twenty years after April 29, 2025, (b) all the Company’s know-how licensed under the Amended Collaboration Agreement has become publicly available through no fault of Takeda, and (c) the expiration of the last valid claim in the intellectual property rights licensed by the Company to Takeda under the Amended Collaboration Agreement covering the Vaccine in Japan. In connection with the Amended Collaboration Agreement, on April 29, 2025, the Company entered into a release agreement with Takeda under which the Company released Takeda and Takeda released the Company from all claims that were asserted or could have been asserted by either party against the other party that related to the Original Agreement and the activities thereunder.

Takeda Pharmaceutical Company Limited Presents at ISCT Annual Meeting 2025, May-07-2025 02:15 PM. Venue: New Orleans, Louisiana, United States. Speakers: Shirley Bartido, Director, Global Regulatory Affairs Oncology Cell Therapy.

Takeda Pharmaceutical Company Limited Presents at 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit, May-13-2025 . Speakers: Pratik Panchal, Head, Translational Medicine, Vinayagam Arunachalam, Director & Head, Computational & Systems Biology, Early Clinical Development.

Hanson Wade Limited, 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit, May 13, 2025 through May 15, 2025.

Rusfertide Ph3 PV data presented at ASCO and commercial opportunity

The company closed its plan on April 21, 2025.

From April 1, 2025 to April 21, 2025, the company has repurchased 11,823,500 shares, representing 0.75% for ¥49,977.96 million. With this, the company has completed the repurchase of 23,367,100 shares, representing 1.47% for ¥99,955.87 million under the buyback announced on January 30, 2025.

Takeda Pharmaceutical Company Limited, 2025 Earnings Call, May 08, 2025

Takeda Pharmaceutical Company Limited Presents at PDA Week 2025, Apr-06-2025 through Apr-11-2025. Venue: Palm Springs, California, United States. Presentation Date & Speakers: Apr-07-2025, Jeff Lewis, Director Global Manufacturing Sciences, Malav Parikh, ME, Director, Quality Risk Management. Apr-08-2025, Antonio Burazer, Global Head Visual Inspection & Particle LCM.

From January 30, 2025 to March 31, 2025, the company has repurchased 11,543,600 shares, representing 0.73% for ¥49,977.91 million. With this, the company has completed the repurchase of 11,543,600 shares, representing 0.73% for ¥49,977.91 million under the buyback announced on January 30, 2025.

Takeda Pharmaceutical Company Limited Presents at Bio-IT World Conference & Expo, Apr-02-2025 . Venue: Boston, United States. Speakers: Felix Francis, Julia Fox, Marcin von Grotthuss, Monica Yangxi Wang, Ophelia Mok.

Mirum Pharmaceuticals Inc. announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI®? (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan. Under the terms of the agreement, Mirum is eligible to receive a percentage of Takeda's annual net sales. LIVMARLI is currently approved for the treatment of pruritus related to ALGS in more than 40 countries and for PFIC in more than 30 countries worldwide.

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2025, Apr 22, 2025 through Apr 24, 2025. Venue: Boston Convention & Exhibition Center, Boston, Massachusetts, United States.

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration (FDA). Key findings from the study include: The primary endpoint of the study was met, with a significantly higher proportion of clinical responders1 among rusfertide-treated patients with PV (77%) compared to those who received placebo (33%) during weeks 20-32; The first key secondary endpoint, which is the pre-specified primary endpoint for European Union (EU) regulators, was also met, with a mean of 0.5 phlebotomies per patient in the rusfertide arm compared to 1.8 phlebotomies per patients in the placebo arm during weeks 0-32; The other three pre-specified key secondary endpoints, namely hematocrit control2 and patient-reported outcomes using PROMIS Fatigue SF-8a3 and MFSAF TSS-74, were also achieved with statistical significance. Rusfertide was generally well tolerated in the Phase 3 VERIFY trial, and safety was in line with previous rusfertide clinical studies. No new safety findings were observed in the study. The milestone is payable following completion of the VERIFY clinical study report. The impact on Takeda's financial results for the fiscal year ending March 31, 2025 (FY2024), following the study results, is immaterial. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health attacks, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's other reports on Takeda's other reported on Takeda's's's other reports filed with the US. Securities and Exchange Commission.

Takeda Pharmaceutical Company Limited Presents at TD Cowen 45th Annual Healthcare Conference, Mar-03-2025 02:30 PM. Venue: Boston Marriot Copley Place, Boston, Massachusetts, United States.

Taiwan Bio Industry Organization, Biotechnology Innovation Organization, BIO Asia Taiwan 2025, Jul 23, 2025 through Jul 28, 2025. Venue: TaiNEX 1 & 2, Taipei Nangang Exhibition Center, Taipei, Taiwan.

Takeda Pharmaceutical Company Limited Presents at ViVE 2025, Feb-16-2025 . Venue: Music City Center, Nashville, Tennessee, United States. Speakers: Gabriele Ricci, Chief Data & Technology Officer.

Takeda Pharmaceutical Company Limited Presents at 17th Annual Outsourcing in Clinical Trials West Coast 2025, Feb-11-2025 . Venue: Hyatt Regency San Francisco Airport, Burlingame, California, United States. Speakers: Bao Dinh, Global Development Business Operation.

Takeda Pharmaceutical Company Limited reported earnings results for the third quarter and nine months ended December 31, 2024. For the third quarter, the company reported sales was JPY 1,144,100 million compared to JPY 1,111,200 million a year ago. Net income was JPY 23,800 million compared to JPY 105,700 million a year ago. Basic earnings per share from continuing operations was JPY 15.01 compared to JPY 67.38 a year ago. For the nine months, sales was JPY 3,528,200 million compared to JPY 3,212,900 million a year ago. Net income was JPY 211,100 million compared to JPY 147,100 million a year ago. Basic earnings per share from continuing operations was JPY 133.71 compared to JPY 94.1 a year ago.

Takeda Pharmaceutical Company Limited announced that they will report fiscal year 2025 results at 3:30 PM, Tokyo Standard Time on May 08, 2025

Takeda Pharmaceutical Company Limited announced that they will report Q1, 2026 results at 3:30 PM, Tokyo Standard Time on Jul 30, 2025

Takeda Pharmaceutical Company Limited Presents at LEAP TA: Life Sciences, Oct-29-2024 03:50 PM. Venue: Boston, Massachusetts, United States. Speakers: Sandy Zou, Talent Intelligence Lead.

Takeda Pharmaceutical Company Limited Presents at 8th Edition Conference of Paris, Dec-16-2024 . Venue: The Organization for Economic Cooperation and Development, France. Speakers: Christophe Weber, President, CEO & Representative Director.

Takeda Pharmaceutical Company Limited Presents at 4th Rare & Genetic Kidney Disease DD Summit, Dec-10-2024 08:30 AM. Venue: Revere Hotel Boston, 200 Stuart St, Boston, Massachusetts, United States. Speakers: Rachel McComb, Sr Manager, Clinical Operations Program Lead, Rare GI2.

Takeda Pharmaceutical Company Limited Presents at EHS&S for Biopharma & Pharma West, Dec-11-2024 09:00 AM. Venue: DoubleTree by Hilton Hotel, Mission Valley 7450 Hazard Center Dr, San Diego, California, United States. Speakers: Obed Varela, Senior Director & Global Head of Environmental Health & Safety, Plasma Derived Therapies.

Takeda Pharmaceutical Company Limited Presents at 14th Annual Injectables Summit, Oct-01-2024 through Oct-03-2024. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: Oct-02-2024, Joyce Zhao, Director, Combination Product Device Development, Richard Braga, SRM/CDMO Lead ­ Devices & Combination Products.

Takeda Pharmaceutical Company Limited announced that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda. Christophe Weber joined Takeda in April 2014 as chief operating officer. He was named president and representative director in June 2014, and subsequently appointed CEO in April 2015. Under Mr. Weber’s leadership, Takeda has focused on enhancing competitiveness through globalization and R&amp;D transformation, while fostering a diverse and inclusive work environment and reinforcing ethical values and corporate governance. Julie Kim has been the president of the U.S. Business Unit and U.S. country head since 2022, and a member of the Takeda Executive Team since 2019. With three decades of experience in health care, Mrs. Kim has held leadership positions at global, regional, country and functional levels. Her extensive background covers a range of therapeutic areas, international market access, general management, marketing and emerging market development. date of birth June 6, 1970; June 2016 joined shire plc. Julie kim representative director, president & chief executive officer appointment is Subject to election and appointment at the 150th Ordinary General Meeting of Shareholders and Board of Directors meeting in June 2026.

Takeda Pharmaceutical Company Limited, Board Meeting, Jan 30, 2025. Agenda: To consider to engage in the acquisition of its own shares.

Takeda announced that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda. Christophe Weber joined Takeda in April 2014 as chief operating officer. He was named president and representative director in June 2014, and subsequently appointed CEO in April 2015. Under Mr. Weber’s leadership, Takeda has focused on enhancing competitiveness through globalization and R&D transformation, while fostering a diverse and inclusive work environment and reinforcing ethical values and corporate governance. Julie Kim has been the president of the U.S. Business Unit and U.S. country head since 2022, and a member of the Takeda Executive Team since 2019. With three decades of experience in health care, Mrs. Kim has held leadership positions at global, regional, country and functional levels. Her extensive background covers a range of therapeutic areas, international market access, general management, marketing and emerging market development.

Takeda announced the decision to discontinue its soticlestat (TAK-935) development program. This decision follows the June 2024 announcement that the soticlestat Phase 3 SKYLINE study in Dravet syndrome (DS) and Phase 3 SKYWAY study in Lennox-Gastaut syndrome (LGS) missed their primary endpoints.1 Subsequently, Takeda discontinued the soticlestat LGS development program 2,3 and engaged with the U.S. Food and Drug Administration (FDA) around the totality of evidence for soticlestat treatment for DS. The FDA informed Takeda that the current clinical data package would not be capable of demonstrating substantial evidence of effectiveness to support a New Drug Application (NDA) for soticlestat in DS.

Takeda Pharmaceutical Company Limited Presents at 2nd Spatial Biology for Drug Development Summit, Oct-24-2024 09:30 AM. Venue: Revere Hotel Boston Common, 200 Stuart St, Bioston, Massachusetts, United States. Speakers: Ali Ebrahimi, Associate Director, Computational and Systems Biology.

Takeda Pharmaceutical Company Limited (TSE:4502) announces a share repurchase program. Under the program, the company will repurchase up to 28,500,000 shares, representing 1.80% of its issued share capital (excluding treasury stock), for ¥100,000 million. The purpose of the program is to enhance capital efficiency and improve shareholder returns. The program is valid till May 31, 2025. As of December 31, 2024, there are 1,585,179,249 issued shares (excluding treasury stock) and 5,758,360 treasury shares.

The Board of Directors of Takeda Pharmaceutical Company Limited has authorized a buyback plan on January 30, 2025.

Takeda Pharmaceutical Company Limited revised earnings guidance for the fiscal year 2024. For the year, the company expects revised revenue of JPY 4,590.0 billion, operating profit of JPY 344.0 billion, net profit of JPY 118.0 billion and EPS of JPY 75 compared to previously expected revenue of JPY 4,480.0 billion, operating profit of JPY 265.0 billion, net profit of JPY 68.0 billion and EPS of JPY 43.

Takeda Pharmaceutical Company Limited Presents at 3rd ESG in Life Sciences Summit, Oct-09-2024 through Oct-11-2024. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: Oct-09-2024, Hollie Grant, Associate Director, Global Sustainability, Kyle Cahill, Senior Director, Environmental Sustainability Disclosure and Engagement Lead. Oct-10-2024, Kristie Boissonneault, Global Senior Manager, Environmental Compliance and Risk and Global Nature Lead. Oct-11-2024, Hollie Grant, Associate Director, Global Sustainability.

Takeda Pharmaceutical Company Limited Presents at 12th IMPACCT RWE Summit, Oct-29-2024 through Oct-31-2024. Venue: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, United States. Presentation Date & Speakers: Oct-30-2024, Ipek Özer Stillman, Head Global Health Economics, Payer Value & Patient Access. Oct-31-2024, Siddharth Jain, Senior Director, Global Medical Unit for Rare Growth & Launch Brands.

Takeda Pharmaceutical Company Limited Presents at World CDx & LBx Summit APAC, Nov-14-2024 11:30 AM. Venue: Conrad Centennial, 2 Temasek Blvd, Singapore , Singapore. Speakers: Jumpei Soeda, Head of Japan Medical Affairs.

Takeda Pharmaceutical Company Limited Presents at 9th CDD For Biologics Summit, Oct-24-2024 09:30 AM. Venue: Hilton Boston Back Bay, 40 Dalton St, Boston, Massachusetts, United States. Speakers: Prashanth Vishwanath, Director and Head of Biologics Informatics & Automation.

Takeda Pharmaceutical Company Limited Presents at 6th Gene Therapy Analytical Development & CMC Summit, Oct-31-2024 12:30 PM. Venue: The Westin Copley Place, 10 Huntington Ave, Boston, Massachusetts, United States. Speakers: Linjing Li, Global Biologics, Research, R&D.

Takeda Pharmaceutical Company Limited Presents at 2024 APAC Commercial Summit, Sep-10-2024 . Venue: Marina Bay Sands, Singapore, Marina Bay, Singapore. Speakers: Danielle Bateman, Head of Data, Digital and Technology, Growth & Emerging Markets, Matt Faulkner, Commercial Capabilities Lead – India & South East Asia, Mikhail Smirnov, Product Owner CRM – GEM.

Neurocrine Biosciences, Inc. announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.

Takeda Pharmaceutical Company Limited Presents at Cell & Gene Therapy Regulatory Affairs Summit, Oct-28-2024 through Oct-30-2024. Venue: Washington Marriott Capitol Hill, 175 L St NE, Washington, D.C., United States. Presentation Date & Speakers: Oct-28-2024, Shirley Bartido, Director, Global Regulatory Affairs & Cell Therapy Oncology. Oct-30-2024, Shirley Bartido, Director, Global Regulatory Affairs & Cell Therapy Oncology.

Takeda Pharmaceutical Company Limited Presents at 6th CNS Drug Delivery Summit, Dec-04-2024 04:00 PM. Venue: Westin Seaport, 425 Summer St, Boston, Massachusetts, United States. Speakers: Sho Sato, Senior Scientist.

Takeda Pharmaceutical Company Limited Presents at ADD Pharmacokinetics & Clinical Pharmacology Summit, Oct-09-2024 09:30 AM. Venue: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, United States. Speakers: Alison Betts, Global Head of DMPK & Modeling.

Takeda Pharmaceutical Company Limited Presents at 2024 APAC Commercial Summit, Sep-18-2024 . Venue: ICC, Sydney, Sydney, Australia. Speakers: Dave Pearce, Head of Portfolio Management - GEM BU.

Takeda Pharmaceutical Company Limited Presents at 3rd Annual Asia | Europe DEI Dialogue 2024, Dec-04-2024 . Speakers: Michelle Erwee, Global Head of Access to Medicine.

Takeda Pharmaceutical Company Limited Presents at Veeva R&D and Quality Summit, Oct-31-2024. Venue: Tokyo, Japan. Presentation Date & Speakers: Oct-31-2024, Junko Kaitoku, Clinical Trial Data Services Clinical Data Management Department Principal, Maiko Shiobara, Clinical Trial Data Services Medical Writing Department Chief.

Takeda Pharmaceutical Company Limited Presents at 5th Annual Future of Pharma Marketing Summit 2024, Oct-23-2024 . Venue: Toronto Airport Marriott Hotel, Toronto, Ontario, Canada. Speakers: Chrisoula Nikidis, Head of Ethics & Compliance Policy Shaping, Inessa Quan, Lead, Patient Services.

Executive Platforms Inc., Pharma Manufacturing World Summit 2025, May 20, 2025 through May 22, 2025. Venue: Boston, Massachusetts, United States.

Parenteral Drug Association, Inc., PDA Week 2025, Apr 06, 2025 through Apr 11, 2025. Venue: Palm Springs, California, United States.

Takeda Pharmaceutical Company Limited Presents at 11th RWE, Market Access, Pricing & Reimbursement 2024 Americas, Oct-30-2024 . Venue: Philadelphia, PA, USA, Philidelphia, Pennsylvania, United States. Speakers: Kellie Murphy, Sr Director, US Patient Value & Market Access - Oncology.

Takeda Pharmaceutical Company Limited Presents at 7th Expanded Access Programmes World Congress 2024 Americas, Nov-14-2024 . Venue: Boston, MA, USA, Boston, Massachusetts, United States. Speakers: Carlos Izquierdo, Global Pricing & Access Lead – Early Pipeline Gastrointestinal.

Takeda Pharmaceutical Company Limited Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 01:30 PM. Venue: The Westin St. Francis Hotel, San Francisco, California, United States.

Takeda Pharmaceutical Company Limited, Q3 2025 Earnings Call, Jan 30, 2025

Hanson Wade Limited, 4th Rare & Genetic Kidney Disease DD Summit, Dec 10, 2024 through Dec 12, 2024. Venue: Revere Hotel Boston, 200 Stuart St, Boston, Massachusetts, United States.

Hanson Wade Limited, EHS&S for Biopharma & Pharma West, Dec 10, 2024 through Dec 11, 2024. Venue: DoubleTree by Hilton Hotel, Mission Valley 7450 Hazard Center Dr, San Diego, California, United States.

Hanson Wade Limited, 6th Gene Therapy Analytical Development & CMC Summit, Oct 30, 2024 through Nov 01, 2024. Venue: The Westin Copley Place, 10 Huntington Ave, Boston, Massachusetts, United States.

Hanson Wade Limited, Cell & Gene Therapy Regulatory Affairs Summit, Oct 28, 2024 through Oct 30, 2024. Venue: Washington Marriott Capitol Hill, 175 L St NE, Washington, D.C., United States.

Cowen Inc., TD Cowen 45th Annual Healthcare Conference, Mar 03, 2025 through Mar 05, 2025. Venue: Boston Marriot Copley Place, Boston, Massachusetts, United States.

Takeda Pharmaceutical Company Limited Presents at Longwood Healthcare Leaders Stanford Summit, Jan-12-2025 01:50 PM. Venue: Four Seasons Hotel San Francisco, 757 Market Street, San Francisco, California, United States. Speakers: Teresa Bitetti, President of the Global Oncology.

Longwood Fund, Longwood Healthcare Leaders Stanford Summit, Jan 11, 2025 through Jan 12, 2025. Venue: Four Seasons Hotel San Francisco, 757 Market Street, San Francisco, California, United States.

Hanson Wade Limited, 6th CNS Drug Delivery Summit, Dec 03, 2024 through Dec 05, 2024. Venue: Westin Seaport, 425 Summer St, Boston, Massachusetts, United States.

Hanson Wade Limited, ADD Pharmacokinetics & Clinical Pharmacology Summit, Oct 08, 2024 through Oct 10, 2024. Venue: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, United States.

Cambridge Healthtech Institute, Inc., Bio-IT World Conference & Expo, Apr 02, 2025 through Apr 04, 2025. Venue: Boston, United States. To showcase the technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine.

Takeda Pharmaceutical Company Limited expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on January 7, 2025).

Takeda Pharmaceutical Company Limited Presents at Festival of Biologics 2024, Oct-15-2024 . Venue: Basel, Switzerland. Speakers: Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT.

Takeda announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) in patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID). The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for less frequent dosing compared to other subcutaneous IG products, while avoiding the need for venous access. The ability to infuse a larger infusion volume is expected to increase administration flexibility for patients with agammaglobulinemia or hypogammaglobulinemia by decreasing the dosing frequency to once every 3 or 4 weeks, as compared to weekly or bi-weekly with conventional SCIG treatments. The approval is based on data from two pivotal Phase 3, open-label, non-controlled studies evaluating the efficacy, safety, tolerability and pharmacokinetics in Japanese subjects with PID. In these studies, the efficacy and safety profile of HYQVIA in 16 patients aged 2 years or older in Japan were evaluated based on the results of the clinical trials. The Geo Mean of IgG trough level at the last 3 visits was 9.494g/L and was maintained at level comparable to treatment with intravenous or subcutaneous immunoglobulin (Geo Mean of IgG trough level 9.624g/L). The major adverse reactions were pyrexia 5 patients (31.3%) and infusion site erythema, injection site erythema, infusion site swelling, infusion site pain, and headache (12.5%). Data from two Phase 3 clinical trials conducted in patients with PID in North America was also included in the submission. With this approval, Takeda is now able to offer a range of SCIG therapies to patients based on their individual administrative needs, reflecting the company’s commitment to offer patients in Japan a broader choice of treatment options. It also follows the announcement of a significant investment to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. HYQVIA is also currently under review in Japan for additional indications. HYQVIA Product Overview in Japan: Brand Nam: - HYQVIA 10% Subcutaneous Injection Set 5g/50mL 10g/100mL 20g/200mL. Generic Name: pH4 Treated Acid Human Globulin (Subcutaneous Injection), Vorhyaluronidase Alfa (Genetical Recombination). Dosage and Administration: Human immunoglobulin G is administered subcutaneously at the same site within approximately 10 minutes after the subcutaneous injection of vorhyaluronidase alfa (genetical recombination). Initiate the treatment with human immunoglobulin G and vorhyaluronidase alfa (genetical recombination) at 1/3 or 1/4 of the doses described below, and then the doses are titrated up. Note that the dosing interval should be extended depending on the doses. Usually, 150 – 600 mg (1.5 – 6 mL)/kg of body weight of human immunoglobulin G is administered once every 3 weeks or 200 – 800 mg (2 – 8 mL)/kg of body weight of human immunoglobulin G is administered once every 4 weeks. Vorhyaluronidase alfa (genetical recombination) is administered at the dose of 80 units (0.5 mL) per 1 g of human immunoglobulin G. The dose and the number of doses per 3 or 4 weeks may be adjusted according to the patient’s condition.

Takeda Pharmaceutical Company Limited announced that they will report Q3, 2025 results on Jan 30, 2025

Alloy Therapeutics Inc. announced strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at Kyoto University. The core technology to differentiate iPSC into immune cells originates from CiRA’s Shin Kaneko’s laboratory. iCAR-T has potential to develop ‘off-the-shelf’ cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy. Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Alloy will leverage synergies across its unique business model to further advance the iCAR-T/NK platform while enabling broader access to the technology for biotech and pharma partners to develop therapies for cancers including solid tumors. Future clinical validation and platform enhancements will further strengthen the platform. To support these efforts, Alloy is establishing a Japanese subsidiary at Shonan Health Innovation Park in Kanagawa Prefecture, to be led by Victor Stone (Yoshihide Ishii) as the Head of Alloy Cell Therapies and Alloy Therapeutics Japan.

Takeda Pharmaceutical Company Limited declared dividend of JPY 98.00 per share for the second quarter-end of fiscal year ending March 31, 2025 compared to JPY 94.00 per share paid a year ago. Scheduled date of dividend payment commencement: December 2, 2024.

Takeda Pharmaceutical Company Limited, ¥ 98.0, Cash Dividend, Mar-28-2025

Takeda Pharmaceutical Company Limited expected to report Q3 2025 results on January 31, 2025. This event was calculated by S&P Global (Created on October 31, 2024).

Takeda Pharmaceutical Company Limited raised earnings guidance for the full year 2024. For the year, the company expects revenue of JPY 4,480.0 billion, Operating Profit of JPY 265.0 billion, Net Profit of JPY 68.0 billion, and EPS of JPY 43 per share, against previous guidance of revenue of JPY 4,350.0 billion, Operating Profit of JPY 225.0 billion, Net Profit of JPY 58.0 billion, and EPS of JPY 37.

Takeda Pharmaceutical Company Limited Presents at Veeva Commercial Summit, Europe, Nov-19-2024 . Venue: Madrid, Spain.

Veeva Systems Inc., Veeva Commercial Summit, Europe, Nov 19, 2024 through Nov 21, 2024. Venue: Madrid, Spain.

Takeda and Boston Medical Center (BMC) announced a new collaboration focused on identifying innovative solutions that can reduce hard-to-abate greenhouse gas (GHG) emissions in the health care sector. The collaboration between Takeda and BMC aims to reduce the GHG emissions caused by disposal of regulated medical waste, such as pharmaceutical packaging and single-use plastics, which are among the most difficult environmental challenges facing the industry. The effort will also seek to scale the interventions developed through the collaboration by sharing best practices to help other organizations adopt and learn new ways to decarbonize in their operations to drive wider health care ecosystem impact. A key objective of this collaboration is to effectively identify, pilot and share valuable insights on decarbonization solutions that other healthcare organizations can adopt as they also seek to reduce greenhouse gas emissions. This may include engaging with other industry stakeholders, such as suppliers, waste vendors, and packaging providers to share and establish new best practices and practical applications. As a part of this collaboration, Boston Medical Center will conduct waste audits across key clinical areas to identify emission hotspots and pilot new technologies aimed at reducing emissions from the disposal of regulated medical waste, including pharmaceutical packaging. BMC, recognized with multiple Practice Greenhealth Top 25 Environmental Excellence Awards, is the first hospital in the nation to leverage a rooftop solar array to provide energy bill credit to eligible patients facing energy insecurity. The hospital built two rooftop farms supplying fresh produce for the hospital's food pantry, patient meals and local community organizations, and opened the first net-zero ready for energy behavioral health facility—among other leading initiatives. BMC was also the first nonprofit health care organization in the country to issue sustainability bonds with a $232 million bond sale for campus renovations to better support patient care. For Takeda, this collaboration supports its ambitious climate goal to reach net-zero greenhouse gas (GHG) emissions in its operations by 2035 and across value chain by 2040. In 2024, the Science Based Targets initiative (SBTi) validated Takeda’s net zero GHG emission goals as being consistent with reductions required to limit the rise in global temperature to 1.5°C above pre-industrial levels.

Takeda Pharmaceutical Company Limited Presents at World Orphan Drug Congress Europe, Oct-22-2024 through Oct-25-2024. Venue: Barcelona, Spain, Barcelona, Spain. Presentation Date & Speakers: Oct-23-2024, Jonathan Neal, Head Pipeline & Portfolio Europe & Canada, Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada.

Takeda Pharmaceutical Company Limited Presents at Longwood Healthcare Leaders Boston, Oct-28-2024 through Oct-29-2024. Venue: Mandarin Oriental, Boston 776 Boylston St, Boston, Massachusetts, United States. Presentation Date & Speakers: Oct-28-2024, Ramona Sequeira, President of Global Portfolio Division. Oct-29-2024, Gina Consylman, R&D, CFO & COO, Pallavi Garg, Head, US Oncology Business Unit, Raj Khunkhun, Head, Neuroscience BD, Sarah Sheikh, Head, Global Development & SVP, Neuroscience.

Biotechnology Innovation Organization, BIO International Convention 2025, Jun 16, 2025 through Jun 19, 2025. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States.

We Arena International Ltd, 17th Annual Outsourcing in Clinical Trials West Coast 2025, Feb 11, 2025 through Feb 12, 2025. Venue: Hyatt Regency San Francisco Airport, Burlingame, California, United States.

Takeda Pharmaceutical Company Limited Presents at DIA Real-World Evidence Conference, Oct-24-2024 . Venue: Philadelphia, Pennsylvania, United States. Speakers: Antonia Electra Panayi, Head, Global Medical Evidence.

Drug Information Association, Inc., DIA Real-World Evidence Conference, Oct 24, 2024 through Oct 25, 2024. Venue: Philadelphia, Pennsylvania, United States.

Takeda Pharmaceutical Company Limited Presents at BioTechX Europe 2024, Oct-09-2024 through Oct-10-2024. Venue: Congress Center Basel, Basel, Switzerland. Presentation Date & Speakers: Oct-09-2024, Frank Thielmann, Head Function of the Future, Philipp Pauli, Country Head Oncology Germany, Saibal Mukherjee, Director, GI/Rare Digital Initatives.

Takeda Pharmaceutical Company Limited, Q2 2025 Earnings Call, Oct 31, 2024

Takeda Pharmaceutical Company Limited Presents at 2024 PDA Pharmaceutical Microbiology Conference, Oct-07-2024 through Oct-09-2024. Venue: Grand Hyatt Washington, Washington, DC, Washington D C, Washington, United States. Presentation Date & Speakers: Oct-08-2024, Liz Brockson, Aseptic Processing and Sterility Assurance Lead, Luyen T Nguyen, Global Sterility Assurance and Microbiology Lead.

Takeda Pharmaceutical Company Limited Presents at CPHI Milan 2024, Oct-09-2024 01:45 PM. Venue: Milan at Stand 6A2, Milan, Italy. Speakers: Jörg Michaelis.

HUTCHMED (China) Limited announced that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare ("MHLW") to manufacture and market FRUZAQLA®? (fruquintinib) for previously treated metastatic colorectal cancer ("CRC"). FRUzaQLA®? is the first novel targeted therapy in Japan to be approved for metastatic CRC, regardless of biomarker status, in over a decade. CRC is the most prevalent type of cancer in Japan, with an estimated 161,000 new cases and 54,000 deaths in 2023, according to the National Cancer Center's statistics. FRUZAQLA® has been approved for the treatment of advanced or recurrent CRC that is neither curable nor resectable and that has progressed after chemotherapy. The approval by the Japanese MHLW was primarily based on results from the Phase FRESCO-2 trial conducted in the US, Europe, Japan and Australia. Data from FRESCO-2 were published in The Lancet in June 2023. Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau. FRUZAQLA® was approved in the US in November 2023 and in Europe in June 2024.

Takeda Pharmaceutical Company Limited Presents at 27th Congress of the European Sleep Research Society (Sleep Europe 2024), Sep-24-2024 . Venue: Seville, Spain, Sevilla, Spain.

Takeda Pharmaceutical Company Limited Presents at BPI 2024, Sep-23-2024 . Venue: Hynes Convention CenterBoston, MA,USA, Masachussetts, Massachusetts, United States. Speakers: Manu Juneja, Director – Global Sustainability, Michael Dolan, Senior Staff Engineer, Sethu Alexander, Associate Director.

Takeda Pharmaceutical Company Limited Presents at Safety Pharmacology Society (SPS) Annual Meeting, Sep-22-2024 . Venue: San Deiego, California, United States. Speakers: Kathy Derakhchan, Director, Head of in Vivo Pharmacology.

Lupin Limited (Lupin) announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin's Lupivon®? and will be available in two strengths - 10 mg and 20 mg. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonopazan in India. Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India1. While prevalence of GERD ranges from 5% to 28.5%, PUD has prevalence in the range of 8%1. Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/co coffee intake, smoking and alcohol consumption.

To discuss Late-Stage Pipeline and Market Opportunity

Takeda Pharmaceutical Company Limited Presents at DPHARM US 2024, Sep-17-2024 . Venue: Philadelphia, PA, Philadelphia, Pennsylvania, United States. Speakers: Dan Eversole, Associate Director, Digital Strategy, Jordan Brayanov, Head, Digital Strategy, Penny Carlson, VP, Head of Global Clinical Development Operations, Shoibal Datta, Head of Digital Health Sciences, Data Sciences Institute, Sriman Banerjee, Executive Director, Head of Diagnostics, Software Devices and Packaging Development.

Safety Pharmacology Society, Safety Pharmacology Society (SPS) Annual Meeting, Sep 22, 2024 through Sep 25, 2024. Venue: San Deiego, California, United States.

Terrapinn Holdings Ltd, BioTechX Europe 2024, Oct 09, 2024 through Oct 10, 2024. Venue: Congress Center Basel, Basel, Switzerland.

Takeda Pharmaceutical Company Limited Presents at Bioprocess International Conference, Sep-24-2024 11:15 AM. Venue: Hynes Convention Center, Boston, Massachusetts, United States. Speakers: Larry Wang, Associate Scientific Fellow, Analytical Development.

European Sleep Research Society, 27th Congress of the European Sleep Research Society (Sleep Europe 2024), Sep 24, 2024 through Sep 27, 2024. Venue: Seville, Spain, Sevilla, Spain.